Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW EBITDA Margin
EBITDA as a percentage of revenue.
Harrow Health, Inc.NASDAQ: HROW
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -37.3%
EBITDA Margin was -37.3% in Q1 FY2026, down 23.3 pp from a year earlier. On a trailing-twelve-month basis it was 11.7%, up 3.4 pp year over year. Over 3 fiscal years it widened by 19.6 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 14.2% for the fiscal year ending Dec 2026, down from 15.2% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -37.3%-60.2 pp QoQ
- Last fiscal yearDec 2025
- 15.2%+4.1 pp YoY
- LTMMar 2026
- 11.7%+3.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -23.3 pp | -17.2 pp | +6.2 pp |
| 1 year | +4.1 pp | -1.0 pp | -5.1 pp |
| 3 years | +19.6 pp | +28.1 pp | +8.5 pp |
| 5 years | +36.2 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 15.2%
- Year-over-year change
- +4.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.2% | +4.1pp |
| FY2024 | 2024-12-31 | 11.1% | +1.9pp |
| FY2023 | 2023-12-31 | 9.2% | +13.6pp |
| FY2022 | 2022-12-31 | -4.4% | -11.5pp |
| FY2021 | 2021-12-31 | 7.0% | — |
EBITDA Margin vs competitors
How HROW compares with its peers on the latest reported figures
- HROW's LTM Mar 2026 EBITDA Margin of 11.7% is the 2nd highest of the 7 companies compared; the peer median is -1971.1%.
- Its year-over-year change of +3.4 pp is the 2nd highest of 6, against a peer median of -231.3 pp.
- Over three fiscal years its change of +19.6 pp compares with a peer median of -183.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 13.9% | +4.5 pp | -5.4 pp | |
| LTM Mar 2026 | 11.7% | +3.4 pp | +19.6 pp | |
| LTM Sep 2026 | -100.7% | -80.8 pp | +219.4 pp | |
| LTM Mar 2026 | -527.0% | -231.3 pp | -361.8 pp | |
| LTM Mar 2026 | -3415.1% | -3156.5 pp | -497.7 pp | |
| LTM Mar 2026 | -18634.1% | -28166.9 pp | — | |
| LTM Mar 2026 | -18676.3% | — | — | |
| FY2025 | — | — | — | |
TTRXTurn Therapeutics Inc. | FY2025 | — | — | — |
| Peer median (excluding HROW) | -1971.1% | -231.3 pp | -183.6 pp | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.48M | 88.6M | 130.19M | 199.61M | 272.3M |
| Cost of Revenue | 18.21M | 25.38M | 39.64M | 49.25M | 67.93M |
| Gross Profit | 54.26M | 63.21M | 90.55M | 150.37M | 204.37M |
| Gross Margin | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| Research & Development | 11.08M | 3.05M | 6.65M | 12.23M | 12.85M |
| Selling, General & Admin | 39.82M | 0 | 0 | 0 | 152.91M |
| Operating Expenses | 52.65M | 61.29M | 90.12M | 141.55M | 165.76M |
| Depreciation & Amortization | 1.74M | 2.83M | 11.14M | 13.05M | 18.91M |
| EBITDA | 5.1M | (3.94M) | 11.95M | 22.13M | 41.36M |
| EBITDA Margin | 7.0% | -4.4% | 9.2% | 11.1% | 15.2% |
| Operating Income | 1.61M | 1.92M | 431K | 8.82M | 38.61M |
| Operating Margin | 2.2% | 2.2% | 0.3% | 4.4% | 14.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.44M | 7.24M | 21.32M | 22.79M | 24.18M |
| Other Income / Expenses | (19.49M) | (15.93M) | (24.14M) | (26.14M) | (40.33M) |
| Income Before Tax | (17.87M) | (14.01M) | (23.71M) | (17.32M) | (1.72M) |
| Pre-Tax Margin | -24.7% | -15.8% | -18.2% | -8.7% | -0.6% |
| Income Tax Expense | 133K | 75K | 701K | 161K | 3.42M |
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Net Margin | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% |
| EPS (Basic) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| EPS (Diluted) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| Weighted Avg Shares | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
| Weighted Avg Shares (Diluted) | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.